10-Q/A: RetinalGenix Q2 2025: Mounting Losses, Urgent Capital Need

RetinalGenix Technologies Inc. reported continued significant net losses and a critical cash shortage for Q2 2025, raising substantial doubt about its ability to continue as a going concern without immediate capital infusion.

Summary

• The company's Q2 2025 10-Q/A filing primarily updates its principal executive office address, with no other changes to the original filing.
• A net loss of $(649,418) was reported for the three months ended June 30, 2025, compared to $(663,633) for the same period in 2024.
• For the six months ended June 30, 2025, the net loss was $(1,236,677), an improvement from $(2,809,509) in the prior year period.
• The accumulated deficit reached approximately $16.7 million as of June 30, 2025.
• Cash balance was critically low at $839 as of June 30, 2025, a decrease from $6,060 at December 31, 2024.
• Total liabilities stood at approximately $2.0 million as of June 30, 2025.
• Research and development expenses decreased significantly by 83% to $14,430 for the three months ended June 30, 2025, and by 84% to $27,644 for the six months ended June 30, 2025, primarily due to a lack of funds.
• Stock-based compensation expenses increased by 19% to $250,189 for the three months ended June 30, 2025, but decreased by 75% to $482,122 for the six months ended June 30, 2025.
• General and administrative expenses increased by 4% to $383,729 for the three months and $724,932 for the six months ended June 30, 2025, driven by increased allocated salaries from Sanovas and marketing for fundraising.
• The company sold 38,222 shares of common stock at $2.25 per share, raising $86,000 during the six months ended June 30, 2025.
• An investor purchased 44,444 shares of common stock at $2.25 per share for $100,000 in August 2025, subsequent to the reporting period.
• Management concluded that disclosure controls and procedures were ineffective as of June 30, 2025, due to a material weakness in internal control over financial reporting related to a lack of segregation of duties.

Sentiment

Score: 2

Explanation: The company faces severe liquidity issues with minimal cash, significant accumulated losses, and a 'going concern' warning. While net loss decreased year-over-year, this was largely due to drastic cuts in R&D, indicating a struggle to fund core operations. The material weakness in internal controls further compounds the negative sentiment.

Positives

• Net loss for the six months ended June 30, 2025, significantly decreased to $(1,236,677) from $(2,809,509) in the prior year, primarily due to lower stock-based compensation and R&D expenses.
• Successfully collected a $150,000 stock subscription receivable in January 2025.
• Raised $86,000 from the sale of common stock during the six months ended June 30, 2025, and an additional $100,000 in August 2025.
• Progress on the Pearl IRB study for wet macular degeneration, with anticipated expansion to multi-state physicians in September 2025 and initial analysis by Q1 2026.
• Continued planning for pharmaceutical clinical studies for RTG-2023 (dry age-related macular degeneration) and RTG-2024 (Alzheimer's syndrome dementia).
• The Delaware Court of Chancery voided and cancelled 3,000,000 shares of Series F preferred stock issued to Halo and Mr. Gerrans, resolving a long-standing dispute.

Negatives

• The company has had net losses since inception and an accumulated deficit of approximately $16.7 million at June 30, 2025.
• Cash balance is critically low at $839 as of June 30, 2025, and is expected to fund operations for only a few days.
• Total liabilities are approximately $2.0 million, with a significant portion owed to related parties ($352,177 to Sanovas, $547,148 to other related parties).
• Substantial doubt exists about the company's ability to continue as a going concern, as it lacks adequate resources to fund operations beyond August 2026 without further capital raising.
• Research and development expenses were significantly cut due to a 'lack of funds,' indicating financial distress impacting core product development.
• Management concluded that disclosure controls and procedures were ineffective as of June 30, 2025, due to a material weakness in internal control over financial reporting (lack of segregation of duties).
• The company has no full-time employees and relies heavily on Sanovas for personnel and infrastructure, indicating limited operational independence.
• No revenues have been generated since inception, and none are expected until product development is complete and regulatory approvals are obtained.

Risks

• **Going Concern Risk:** Substantial doubt about the company's ability to continue as a going concern due to minimal cash ($839 at June 30, 2025), significant liabilities ($2.0 million), and expected operating losses for several years.
• **Funding Risk:** Inability to raise additional funding on favorable terms or at all, which could force delays, reductions, or termination of product development and commercialization efforts.
• **Regulatory Approval Risk:** No assurance that products under development (RetinalGenixTM) will be cleared for sale by the FDA or other regulatory bodies. RetinalCamTM is anticipated not to require FDA clearance.
• **Commercialization Risk:** No assurance that cleared products will be successfully commercialized, leading to uncertainty regarding future profitability.
• **Internal Control Weakness:** Material weakness in internal control over financial reporting due to lack of segregation of duties, which could lead to inaccurate financial reports and regulatory sanctions.
• **Reliance on Related Parties:** Heavy dependence on Sanovas and other related parties for financing and operational support, which may not be sustainable or on favorable terms.
• **Limited Operating History:** The company is a new business enterprise (formed in 2017) with inherent risks associated with development and expansion.

Future Outlook

The company expects continued operating losses and negative cash flows for at least the next several years. It anticipates needing approximately $6.0 million in additional capital to complete product design and testing for RetinalGenixTM (including FDA submission), develop DNA/GPS genetic mapping software, and build infrastructure for sustained growth. Funding is expected through equity/debt offerings and potential strategic partnerships, but there is no assurance of availability on favorable terms. No revenues are expected until product development is complete and regulatory approval for RetinalGenixTM is obtained.

Management Comments

• "We anticipate an expansion of the IRB to multistate physicians in September 2025."
• "We anticipate the initial analysis by the first quarter 2026, which will allow us to plan for our clinical trials."
• "We expect that operating losses and negative cash flows from operations will occur for at least the next several years, and the Company will need to access additional funds to achieve its strategic goals."
• "We are in discussions with investment bankers and individual investors with respect to raising additional capital for the Company and potentially up-listing to Nasdaq exchange."
• "As of the date of this report, the Company does not have adequate resources to fund its operations through August 2026 without considering any potential future milestone payments... or any future capital raising transactions."
• "The Company will need to raise additional funding to complete the development of its products and commence the market launch, assuming regulatory approval is obtained."
• "Our management has concluded that our internal controls over financial reporting were, and continue to be, ineffective, and as of June 30, 2025 as a result of a material weakness in our internal controls."
• "We hope to complete the implementation, remediation and test of the new procedures in the second half of 2025, as resources permit us to spend time and money on building finance infrastructure."

Industry Context

RetinalGenix operates in the highly competitive and capital-intensive ophthalmic and medical device development industry, with a focus on diagnostic and treatment technologies for eye disorders, including diabetic retinopathy, maculopathy, dry AMD, and even Alzheimer's. The integration of genetic mapping (DNA/GPS Inc.) with retinal imaging positions the company in the emerging field of personalized medicine and early disease detection, aiming to reduce reliance on expensive diagnostic equipment. However, as an early-stage company with no revenue and significant funding challenges, it faces substantial hurdles in a market dominated by established pharmaceutical and medical technology firms.

Comparison to Industry Standards

• The company's lack of revenue and significant accumulated deficit ($16.7 million) is typical for early-stage biotechnology and medical device companies focused on R&D, but its minimal cash balance ($839) and heavy reliance on related party financing are concerning compared to peers that typically secure larger funding rounds to sustain operations for longer periods.
• The substantial reduction in R&D expenses (83-84% decrease) due to 'lack of funds' is a red flag, indicating that critical product development is being hampered, which is not standard for companies actively pursuing FDA clearance and clinical trials.
• The identified material weakness in internal control over financial reporting (lack of segregation of duties) is a significant governance issue that would be considered below industry best practices for public companies, regardless of size.
• The company's stated need for an additional $6.0 million for product development and infrastructure is a relatively modest amount for the scope of its stated goals (FDA clearance, clinical trials for two drug candidates, DNA/GPS software expansion), suggesting a potentially underestimated capital requirement compared to typical industry benchmarks for such endeavors.

Management Changes

Corporate Governance

Legal Proceedings

• The company received a claim relating to a former indirect vendor, which it believes is without merit and intends to vigorously defend. It does not believe the claim would have a material impact on its financial condition.
• The Delaware Action against Lawrence Gerrans and Halo Management LLC, seeking to void equity rights, was resolved on April 2, 2024, with the court voiding and cancelling the 3,000,000 shares of Series F preferred stock.

Related Party Transactions

• Sanovas Ophthalmology, LLC, a majority-owned subsidiary of Sanovas Inc., formed the company and sublicensed certain technology.
• Sanovas Inc. invoices the company for costs and expenses paid on its behalf and allocated costs for shared services.
• Sanovas was owed approximately $352,177 as of June 30, 2025, an increase from $15,709 at the beginning of the period.
• Costs of Sanovas allocated to the company for the six months ended June 30, 2025, amounted to $330,750 (compared to $415,800 in 2024).
• Cash advances from Sanovas to the company, net, were $5,718 for the six months ended June 30, 2025.
• An officer of the company, a shareholder, and other related parties advanced funds or paid expenses, totaling $547,148 at June 30, 2025 (up from $467,793 at December 31, 2024).
• Shareholder notes payable of $49,000 remained outstanding at June 30, 2025, with an informally extended maturity date to December 31, 2026.
• Jerry Katzman, the company's CEO, is also a director and CEO of Sanovas.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from future capital raises, substantial doubt about the company's going concern ability, and uncertainty regarding product commercialization and profitability. The material weakness in internal controls could erode confidence.
• **Creditors (especially related parties):** High exposure due to significant amounts owed to Sanovas and other related parties, with no formal repayment plan for some advances.
• **Employees (if any, though none full-time):** The company has no full-time employees and relies on Sanovas, indicating limited direct impact, but future hiring is contingent on funding.
• **Customers/Patients:** Potential delays in product development and market launch due to funding issues could impact the availability of new diagnostic and treatment technologies.

Next Steps

• Expand the Pearl IRB study to multi-state physicians (anticipated September 2025).
• Conduct initial analysis of Pearl IRB study results (anticipated Q1 2026) to plan for clinical trials.
• Continue planning and guidance for pharmaceutical clinical studies for RTG-2023 (dry AMD) and RTG-2024 (Alzheimer's syndrome dementia).
• Complete product design and testing for RetinalGenixTM and RetinalCamTM.
• Submit RetinalGenixTM for FDA clearance.
• Complete development and expansion of software tools for DNA/GPS genetic mapping technology.
• Build infrastructure for sustained growth.
• Raise approximately $6.0 million in additional capital through equity/debt offerings or strategic partnerships.
• Implement remediation measures to address the material weakness in internal control over financial reporting (hiring internal accounting resources or using outside providers, implementing a more formal accounting system) in the second half of 2025, as resources permit.
• Potentially up-list to Nasdaq exchange.

Key Dates

Recommendation

The company is in a precarious financial position with a critically low cash balance ($839), significant liabilities, and an explicit 'going concern' warning. The drastic reduction in R&D spending due to lack of funds directly undermines its core mission of product development. While the net loss decreased, this was achieved by cutting essential development activities. The material weakness in internal controls further highlights operational deficiencies. The need for $6.0 million in additional capital is urgent, and there's no guarantee of securing it on favorable terms. Given the severe liquidity crisis, operational challenges, and high uncertainty, the stock carries extreme risk.

Keywords

Ophthalmic Technology, Retinal Imaging, Medical Devices, Diabetic Retinopathy, Maculopathy, Alzheimer's Treatment, Dry AMD, Genetic Mapping, Biotechnology, SEC Filing, Going Concern, Capital Raise, Clinical Trials, FDA Clearance